[1]
|
Bolton-Maggs, P.H. and Pasi, K.J. (2003) Hemophilias A and B. Lancet, 361, 1801-1809.
https://doi.org/10.1016/S0140-6736(03)13405-8
|
[2]
|
White, G., Rosendaal, F., Aledort, L.M., et al. (2001) Defini-tions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis, 85, 560.
https://doi.org/10.1055/s-0037-1615621
|
[3]
|
Recht, M., Nemes, L., Matysiak, M., et al. (2009) Clinical Evaluation of Moroctocog Alfa (AF-CC), a New Generation of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII) for Treatment of Haemophilia A: Demonstration of Safety, Efficacy, and Pharmacokinetic Equivalence to Full-Length Re-combinant Factor VIII. Haemophilia, 15, 869-880. https://doi.org/10.1111/j.1365-2516.2009.02027.x
|
[4]
|
Lentz, S.R., Misgav, M., Ozelo, M., et al. (2013) Results from a Large Multinational Clinical Trial (Guardian™1) Using Prophylactic Treatment with turoctocog Alfa in Adolescent and Adult Patients with Severe Haemophilia A: Safety and Efficacy. Haemophilia, 19, 691-697. https://doi.org/10.1111/hae.12159
|
[5]
|
Kulkarni, R., Karim, F.A., Glamocanin, S., et al. (2013) Results from a Large Multinational Clinical Trial (Guardian™3) Using Prophylactic Treatment with Turoctocog Alfa in Paediatric Patients with Severe Haemophilia A: safety, Efficacy and Pharmacokinetics. Haemophilia, 19, 698-705. https://doi.org/10.1111/hae.12165
|
[6]
|
Ozelo, M., Misgav, M., Abdul Karim, F., et al. (2015) Long-Term Patterns of Safety and Efficacy of Bleeding Prophylaxis with Turoctocog Alfa (NovoEight®) in Previously Treated Patients with Severe Haemophilia A: Interim Results of the Guardian™2 Extension Trial. Haemophilia, 21, e436-e439. https://doi.org/10.1111/hae.12737
|
[7]
|
Hassan, Y., Tadashi, M., Meriem, B., et al. (2020) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeds in Previously Untreated Paediatric Patients with Severe Haemophilia A: Results from the Guardian 4 Multinational Clinical Trial. Haemophilia, 26, 64-72. https://doi.org/10.1111/hae.13883
|
[8]
|
Saxena, K., Lalezari, S., Oldenburg, J., Tseneklidou-Stoeter, D., Beckmann, H., Yoon, M. and Maas Enriquez, M. (2016) Efficacy and Safety of BAY 81-8973, a Full-Length Recombinant Factor VIII: Results from the LEOPOLD I Trial. Haemophilia, 22, 706-712. https://doi.org/10.1111/hae.12952
|
[9]
|
Kavakli, K., Yang, R., Rusen, L., Beckmann, H., Tseneklidou-Stoeter, D. and Maas Enriquez, M. (2015) Prophylaxis vs. On-Demand Treatment with BAY 81-8973, a Full-Length Plasma Pro-tein-Free Recombinant Factor VIII Product: Results from a Randomized Trial (LEOPOLD II). Journal of Thrombosis and Haemostasis, 13, 360-369.
|
[10]
|
Ljung, R., Kenet, G., Mancuso, M.E., et al. (2016) BAY 81-8973 Safety and Effi-cacy for Prophylaxis and Treatment of Bleeds in Previously Treated Children with Severe Haemophilia A: Results of the LEOPOLD Kids Trial. Haemophilia, 22, 354-360. https://doi.org/10.1111/hae.12866
|
[11]
|
Zollner, S.B., Raquet, E., Müller-Cohrs, J., et al. (2013) Preclinical Efficacy and Safety of rVIII-SingleChain (CSL627), a novel recombinant sin-gle-chain factor VIII. Thrombosis Research, 132, 280-287.
https://doi.org/10.1016/j.thromres.2013.06.017
|
[12]
|
Klamroth, R., Simpson, M., von Depka-Prondzinski, M., et al. (2016) Comparative Pharmacokinetics of rVIII-SingleChain and Octocog Alfa (Advate®) in Patients with Severe Hae-mophilia A. Haemophilia, 22, 730-738.
https://doi.org/10.1111/hae.12985
|
[13]
|
Mahlangu, J., Kuliczkowski, K., Karim, F.A., et al. (2016) Efficacy and Safety of rVIII-SingleChain: Results of a Phase 1/3 Multicenter Clinical Trial in Severe Hemophilia A. Blood, 128, 630-637.
https://doi.org/10.1182/blood-2016-01-687434
|
[14]
|
Liesner, R.J., Abashidze, M., Aleinikova, O., et al. (2018) Immunogenicity, Efficacy and Safety of Nuwiq® (Human-cl rhFVIII) in Previously Untreated Patients with Severe Haemophilia A—Interim Results from the NuProtect Study. Haemophilia, 24, 211-220. https://doi.org/10.1111/hae.13320
|
[15]
|
Klukowska, A., Szczepański, T., Vdovin, V., et al. (2016) Novel, Human Cell Line-Derived Recombinant Factor VIII (Human-cl rhFVIII, Nuwiq®) in Children with Severe Haemophilia A: Effi-cacy, Safety and Pharmacokinetics. Haemophilia, 22, 232-239. https://doi.org/10.1111/hae.12797
|
[16]
|
Lissitchkov, T., Hampton, K., von Depka, M., et al. (2016) Novel, Human Cell Line-Derived Recombinant Factor VIII (Hu-man-clrhFVIII; Nuwiq®) in Adults with Severe Haemophilia A: Efficacy and Safety. Haemophilia, 22, 225-231.
https://doi.org/10.1111/hae.12793
|
[17]
|
Kitchen, S., Kershaw, G. and Tiefenbacher, S. (2016) Recombinant to Modified Factor VIII and Factor IX-Chromogenic and One-Stage Assays Issues. Haemophilia, 22, 72-77. https://doi.org/10.1111/hae.13012
|
[18]
|
Coyle, T.E., Reding, M.T., Lin, J.C., Michaels, L.A., Shah, A. and Powell, J. (2014) Phase I study of BAY 94-9027, a PEGylated B-Domain-Deleted Recombinant Factor VIII with an Extended Half-Life, in Subjects with Hemophilia A. Journal of Thrombosis and Haemostasis, 12, 488-496. https://doi.org/10.1111/jth.12506
|
[19]
|
Reding, M.T., Ng, H.J., Poulsen, L.H., et al. (2017) Safety and Efficacy of BAY 94-9027, a Prolonged-Half-Life Factor VIII. Journal of Thrombosis and Haemostasis, 15,411-419. https://doi.org/10.1111/jth.13597
|
[20]
|
Tiede, A., Brand, B., Fischer, R., et al. (2013) Enhancing the Pharmacoki-netic Properties of Recombinant Factor VIII: First-In-Human Trial of glycoPEGylated Recombinant Factor VIII in Pa-tients with Hemophilia A. Journal of Thrombosis and Haemostasis, 11, 670-678. https://doi.org/10.1111/jth.12161
|
[21]
|
Hampton, K., Chowdary, P., Dunkley, S., et al. (2017) First Report on the Safety and Efficacy of an Extended Half-Life glycoPEGylated Recombinant FVIII for Major Surgery in Severe Haemo-philia A. Haemophilia, 23, 689-696.
https://doi.org/10.1111/hae.13246
|
[22]
|
Mahlangu, J.N., Ragni, M., Gupta, N., et al. (2016) Long-Acting Recom-binant Factor VIII Fc Fusion Protein (rFVIIIFc) for Perioperative Haemostatic Management in Severe Haemophilia A. Thrombosis and Haemostasis, 116, 1-8.
https://doi.org/10.1160/TH15-10-0780
|
[23]
|
Mahlangu, J., Powell, J.S., Ragni, M.V., et al. (2014) Phase 3 Study of Recombinant Factor VIII Fc Fusion Protein in Severe Hemophilia A. Blood, 123, 317-325. https://doi.org/10.1182/blood-2013-10-529974
|
[24]
|
Young, G., Mahlangu, J., Kulkarni, R., et al. (2015) Recom-binant Factor VIII Fc Fusion Protein for the Prevention and Treatment of Bleeding in Children with Severe Hemophilia A. Journal of Thrombosis and Haemostasis, 13, 967-977.
https://doi.org/10.1111/jth.12911
|
[25]
|
Nolan, B., Mahlangu, J., Perry, D., et al. (2016) Long-Term Safety and Ef-ficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects with Haemophilia A. Haemophilia, 22, 72-80. https://doi.org/10.1111/hae.12766
|
[26]
|
Xue, F., Zhao, X., Sun, J., et al. (2021) Pharmacokinetic, Efficacy and Safety Evaluation of B-Domain-Deleted Recombinant FVIII (SCT800) for Prophylactic Treatment in Adolescent and Adult Patients with Severe Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.14350
|